Epidemiology of Pulmonary Aspergillosis in Hospitalized Patients in Poland During 2009–2016

Advances in Pulmonary Medicine: Research and Innovations - Advances in Experimental Medicine and Biology ◽

10.1007/5584_2019_347 ◽

2019 ◽

pp. 73-80 ◽

Cited By ~ 1

Author(s):

Patryk Tarka ◽

Aneta Nitsch-Osuch ◽

Paweł Gorynski ◽

Piotr Tyszko ◽

Magdalena Bogdan ◽

...

Keyword(s):

Hospitalized Patients ◽

Pulmonary Aspergillosis

Download Full-text

A Fatal Case of Rhizopus azygosporus Pneumonia Following COVID-19

Journal of Fungi ◽

10.3390/jof7030174 ◽

2021 ◽

Vol 7 (3) ◽

pp. 174

Author(s):

Anubhav Kanwar ◽

Alex Jordan ◽

Scott Olewiler ◽

Kurt Wehberg ◽

Michael Cortes ◽

...

Keyword(s):

Fatal Case ◽

Hospitalized Patients ◽

Pulmonary Aspergillosis

We report a fatal case of Rhizopus azygosporus pneumonia in a 56-year-old man hospitalized for COVID-19 who had received methylprednisolone and tocilizumab. Although COVID-associated pulmonary aspergillosis has been widely documented, mucormycosis has been rarely reported. In this patient, receipt of two commonly used immunosuppressants likely contributed to mucormycosis risk, suggesting the need for vigilance in hospitalized patients with COVID-19.

Download Full-text

987. Clinical Epidemiology and Outcomes of Invasive Pulmonary Aspergillosis as a Complication of Respiratory Viral Infection in Hospitalized Patients

Open Forum Infectious Diseases ◽

10.1093/ofid/ofab466.1181 ◽

2021 ◽

Vol 8 (Supplement_1) ◽

pp. S584-S584

Author(s):

Bertha A De Los Santos ◽

Brian J Barnes ◽

Nicholas Britt

Keyword(s):

Kansas City ◽

Viral Infections ◽

Clinical Epidemiology ◽

Invasive Pulmonary Aspergillosis ◽

Hospitalized Patients ◽

Pulmonary Aspergillosis ◽

All Cause Mortality ◽

Syncytial Virus ◽

One Year ◽

The University

Abstract Background Invasive pulmonary aspergillosis (IPA) is increasingly recognized as a complication of severe respiratory viral infections (RVIs), including influenza and COVID-19. However, the incidence and outcomes of IPA following other RVIs is not well-described. We hypothesized that IPA may be an underreported complication of non-influenza RVIs. The objective of this study was to quantify the incidence and associated outcomes of IPA following RVI in hospitalized patients. Methods We conducted a single-center retrospective cohort study of adult hospitalized patients with RVI diagnosed by multiplex PCR-based assay at the University of Kansas Hospital (Kansas City, Kansas) from September 2018-October 2019. Patients with a diagnosis of proven or probable IPA prior to RVI and those with hospital admission < 24 h were excluded from analysis. Proven or probable IPA was defined according to EORTC/MSGERC consensus definitions. The primary outcome was 1-year all-cause mortality. Results A total of 195 patients met study criteria and were included in the analysis. The most common types of RVI observed were rhinovirus/enterovirus (57.9%, n=113), parainfluenza (13.3%, n=26), influenza (8.2%, n=16), and respiratory syncytial virus (7.7%, n=15). The cumulative incidence of IPA infection within 6 weeks of RVI was 5.6% (n=11). Excluding patients co-infected with multiple respiratory viruses (n=5), IPA was numerically more likely to occur following influenza compared to non-influenza RVI (12.5% [ n=2/16] vs. 4.6% [n=8/174]; odds ratio, 2.96; 95% confidence interval [CI], 0.57-15.3; P=0.176). Overall, one-year all-cause mortality was 20% (n=39/195) in this cohort. Development of IPA as a complication of RVI was associated with a significant decrease in 1-year survival (hazard ratio [HR], 3.04; 95% CI, 1.19-7.78; P=0.021), and this relationship persisted after adjustment for age (HR, 2.77; 95% CI, 1.08-7.10; P=0.034). Conclusion In a cohort of hospitalized patients with RVI, 5.6% of patients developed proven or probable IPA. Although IPA was more likely to occur in patients with influenza, this complication was also observed with other types of RVI. Invasive pulmonary aspergillosis may be an underappreciated complication of non-influenza RVI in hospitalized patients and warrants continued study. Disclosures All Authors: No reported disclosures

Download Full-text